Guggenheim analyst Yatin Suneja reiterates Larimar Therapeutics (NASDAQ:LRMR) with a Buy and maintains $12 price target.
Stocks Notch 4th Week Of Gains – Tech Falters As Yields Rise; Gold Steady At $2,000: Friday’s Market Recap
U.S. stocks marked their fourth consecutive week of gains, the longest winning streak since June, in a week marked by thinner trading volumes due to the Thanksgiving and Black Friday holidays.
